Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
umbilical cord mesenchymal stem cells (Zhongnan Hospital of Wuhan University)
- Development stage
- Unknown
- Lead developer
- Zhongnan Hospital of Wuhan University
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
UC-MSCs-ZhiYong Peng-COVID-19 pneumonia refers to an investigational cell therapy utilizing allogeneic umbilical cord-derived mesenchymal stem cells (UC-MSCs) for the treatment of severe and critical COVID-19 pneumonia. Developed by Dr. Zhiyong Peng and his team at Zhongnan Hospital of Wuhan University, the therapy is administered intravenously to leverage the cells' innate immunomodulatory, anti-inflammatory, and regenerative properties. The primary mechanism involves the mitigation of the systemic hyperinflammatory state, often referred to as a "cytokine storm," by reducing the levels of pro-inflammatory cytokines (such as TNF-α and IL-6) and promoting an anti-inflammatory environment. Clinical results from Phase 2 pilot studies have demonstrated the safety of this approach and suggested potential benefits in improving oxygenation, reducing lung pathology, and lowering mortality rates in critically ill patients.
- Other names
- hUC-MSCshuman umbilical cord mesenchymal stem cellsUC-MSCs-ZhiYong Peng-COVID-19 pneumonia
Beyond the preview
Go deeper on umbilical cord mesenchymal stem cells (Zhongnan Hospital of Wuhan University).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on umbilical cord mesenchymal stem cells (Zhongnan Hospital of Wuhan University).